Cargando…
Favipiravir elicits antiviral mutagenesis during virus replication in vivo
Lethal mutagenesis has emerged as a novel potential therapeutic approach to treat viral infections. Several studies have demonstrated that increases in the high mutation rates inherent to RNA viruses lead to viral extinction in cell culture, but evidence during infections in vivo is limited. In this...
Autores principales: | Arias, Armando, Thorne, Lucy, Goodfellow, Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204012/ https://www.ncbi.nlm.nih.gov/pubmed/25333492 http://dx.doi.org/10.7554/eLife.03679 |
Ejemplares similares
-
Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis
por: Thorne, Lucy, et al.
Publicado: (2016) -
Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
por: Bosaeed, Mohammad, et al.
Publicado: (2021) -
Roles for mycobacterial DinB2 in frameshift and substitution mutagenesis
por: Dupuy, Pierre, et al.
Publicado: (2023) -
Human influenza virus infection elicits distinct patterns of monocyte and dendritic cell mobilization in blood and the nasopharynx
por: Vangeti, Sindhu, et al.
Publicado: (2023) -
Transposon mutagenesis in Mycobacterium abscessus identifies an essential penicillin-binding protein involved in septal peptidoglycan synthesis and antibiotic sensitivity
por: Akusobi, Chidiebere, et al.
Publicado: (2022)